1. Home
  2. ONC vs MRNA Comparison

ONC vs MRNA Comparison

Compare ONC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • MRNA
  • Stock Information
  • Founded
  • ONC 2010
  • MRNA 2010
  • Country
  • ONC Cayman Islands
  • MRNA United States
  • Employees
  • ONC N/A
  • MRNA N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • MRNA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ONC Health Care
  • MRNA Health Care
  • Exchange
  • ONC Nasdaq
  • MRNA Nasdaq
  • Market Cap
  • ONC 19.3B
  • MRNA 16.0B
  • IPO Year
  • ONC N/A
  • MRNA 2018
  • Fundamental
  • Price
  • ONC $255.37
  • MRNA $35.53
  • Analyst Decision
  • ONC
  • MRNA Hold
  • Analyst Count
  • ONC 0
  • MRNA 20
  • Target Price
  • ONC N/A
  • MRNA $59.65
  • AVG Volume (30 Days)
  • ONC 357.2K
  • MRNA 13.6M
  • Earning Date
  • ONC 02-27-2025
  • MRNA 02-14-2025
  • Dividend Yield
  • ONC N/A
  • MRNA N/A
  • EPS Growth
  • ONC N/A
  • MRNA N/A
  • EPS
  • ONC N/A
  • MRNA N/A
  • Revenue
  • ONC $3,351,304,621.00
  • MRNA $3,236,000,000.00
  • Revenue This Year
  • ONC $992.37
  • MRNA N/A
  • Revenue Next Year
  • ONC $24.68
  • MRNA $22.19
  • P/E Ratio
  • ONC N/A
  • MRNA N/A
  • Revenue Growth
  • ONC 50.22
  • MRNA N/A
  • 52 Week Low
  • ONC $126.97
  • MRNA $29.25
  • 52 Week High
  • ONC $260.98
  • MRNA $170.47
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • MRNA 48.60
  • Support Level
  • ONC N/A
  • MRNA $32.78
  • Resistance Level
  • ONC N/A
  • MRNA $36.98
  • Average True Range (ATR)
  • ONC 0.00
  • MRNA 2.50
  • MACD
  • ONC 0.00
  • MRNA 0.30
  • Stochastic Oscillator
  • ONC 0.00
  • MRNA 66.81

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: